Dear colleagues, friends and readers of this site, I learned with some amazement and dismay just before the well-deserved summer holidays some important news regarding the Takeda and Nycomed mobilities.
I must note that with suspicious timing to say the least, i.e. close to the month of August, in which everyone yearns only for a well-deserved rest after the hard work of an entire year, these two companies have communicated to the workers and trade union organizations their willingness to make draconian cuts in their employees.
From the news on the internet it has been learned that 170 are made redundant in Takeda out of 545 employees and that 124 are made redundant out of 219 employees in Nycomed.
Just re-reading these numbers makes you shiver even with the heat of the last period, but unfortunately it's not a joke in bad taste, but a sad reality. What has been happening in our sector lately is unfortunately a film we have already seen. Many pharmaceutical companies, increasingly greedy for profits, unload thousands of workers who are now considered useless for their needs onto the entire community.
With a typically arrogant attitude, companies in this sector complain that the role of the ISF has changed, and that it is now considered outdated. They now need only small organizational structures with a very high scientific profile.
But so far what were these isfs, by any chance amateurs in jeopardy?
And the professional titles such as the scientific degrees required in this profession by pharmaceutical companies, what were a tinsel to be included in a business card?
